(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 5.25% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Collegium Pharmaceutical's revenue in 2025 is $631,449,000.On average, 4 Wall Street analysts forecast COLL's revenue for 2025 to be $23,342,737,042, with the lowest COLL revenue forecast at $23,201,052,188, and the highest COLL revenue forecast at $23,546,763,231. On average, 4 Wall Street analysts forecast COLL's revenue for 2026 to be $24,274,928,921, with the lowest COLL revenue forecast at $23,472,457,397, and the highest COLL revenue forecast at $25,113,482,855.
In 2027, COLL is forecast to generate $22,639,035,603 in revenue, with the lowest revenue forecast at $18,522,933,181 and the highest revenue forecast at $26,091,108,344.